DiaMedica Therapeutics Inc. (DMAC)

NASDAQ: DMAC · IEX Real-Time Price · USD
1.97
+0.07 (3.68%)
Aug 12, 2022 4:00 PM EDT - Market closed

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year 202120202019201820172016
Revenue
0000.500
Gross Profit
0000.500
Selling, General & Admin
4.884.493.692.741.310.6
Research & Development
8.778.217.94.523.211.73
Operating Expenses
13.6512.711.597.264.522.33
Operating Income
-13.65-12.7-11.59-6.76-4.52-2.33
Other Expense / Income
-0.03-0.43-0.98-1.11-0.26-0.11
Pretax Income
-13.61-12.27-10.62-5.65-4.26-2.22
Income Tax
0.030.030.030.0800
Net Income
-13.64-12.3-10.65-5.73-4.26-2.22
Net Income Common
-13.64-12.3-10.65-5.73-4.26-2.22
Shares Outstanding (Basic)
211612865
Shares Outstanding (Diluted)
211612865
Shares Change
32.48%30.80%54.81%30.45%25.34%-
EPS (Basic)
-0.65-0.78-0.89-0.74-0.72-0.47
EPS (Diluted)
-0.65-0.78-0.89-0.74-0.72-0.47
Free Cash Flow Per Share
-0.59-0.59-0.76-0.74-0.66-0.63
Gross Margin
---100.00%--
Operating Margin
----1352.20%--
Profit Margin
----1146.80%--
Free Cash Flow Margin
----1149.20%--
Effective Tax Rate
-0.21%-0.22%-0.29%-1.41%0.00%0.00%
EBITDA
-13.53-12.2-10.55-5.64-4.26-2.22
EBITDA Margin
----1127.80%--
Depreciation & Amortization
0.080.070.070.0200
EBIT
-13.61-12.27-10.62-5.65-4.26-2.22
EBIT Margin
----1130.80%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).